10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).
AGM Trading Update
Posting of Annual Report and Accounts and Notice of AGM
18 August 2020: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2020 and the Notice of the 2020 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.
A copy of the Annual Report can be found by clicking here.
Notification of Allowance granted for US patent
31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.
Preliminary Results for the year ended 31 March 2020
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
A recording of the webcast can be accessed via the following link:
https://webcasting.buchanan.uk.com/broadcast/5f154afa4c167c1215797e02
The presentation can be accessed by clicking here.
Further positive data in retinal clinical trial
Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment
29 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and ultimately blindness.
ReNeuron signs new exosome research collaboration
25 June 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.
Regulatory approvals and programme update
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
ReNeuron’s CTX cell line shows further potential
Newly published positive efficacy data in an accepted model of Huntington’s disease
07 May 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled “Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington’s disease”.
Exosome Research Collaboration
07 April 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.
COVID-19 Update
03 April 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of UK and US government measures to contain the spread of the disease.